Russia’s Sputnik Light vaccine, which received regulatory approval on Thursday, will be priced at less than $10. The single-dose version of the country’s Sputnik V vaccine has demonstrated 79.4 percent efficacy in a real-world study as part of Russia’s mass vaccination campaign. The Russian authorities argued that the move could accelerate the process of achieving herd immunity against the coronavirus.
Sputnik Light, identical to the first dose of the two-dose Sputnik V, has yet to complete the advanced testing needed to ensure its safety and effectiveness in line with established scientific protocols. The human trials of Sputnik Light were started in January, and the studies are underway, as per the official records.
A heterologous vaccine regimen, Sputnik V uses two different adenoviruses for the first and the second dose of vaccine. The prime or the first dose is rAd26 and the second or booster dose consists of rAd5. The new version, Sputnik Light is Sputnik V’s prime dose rAd26 and has been approved as a standalone vaccine.
Sputnik Light became the fourth COVID-19 vaccine, developed domestically, to get approval in Russia. Commenting on the decision to authorize it for use, President Vladimir Putin said Thursday, “It’s nice to know that this range of tools (against COVID-19) is expanding."
Russian Health Minister Mikhail Murashko said authorizing a fourth jab will help speed up the process of forming herd immunity against the virus. Most scientists believe at least 70% of a population needs to be immunized to achieve herd immunity against COVID-19, but the exact threshold is still unknown.
Russia faced criticism last year for authorising Sputnik V before advanced trials had even started and for offering it to medical workers while those trials were underway. The criticism was blunted by a study published in February in the British medical journal The Lancet, which said the vaccine appeared safe and 91% effective against COVID-19 based on a trial involving about 20,000 people in Russia.
Two other Russian vaccines EpiVacCorona and CoviVac also received regulatory approval before completing large-scale testing. No data on the efficacy of the vaccines has been released.
Despite having several vaccines available and being one of the first countries to start immunizing its population, Russia is currently lagging behind a number of nations in terms of its vaccination rates.
According to Deputy Prime Minister Tatyana Golikova, 13.4 million people in Russia, or just 9% of Russia’s population of 146 million, had received at least one dose of a COVID-19 vaccine as of Thursday, while 9.4 million 6% of the population have been fully vaccinated.
Experts have questioned whether Russia will be able to meet the government’s targets of vaccinating 30 million people by mid-June and nearly 69 million by August.
(With inputs from AP)